AstraZeneca Stock News

Jefferies maintained a 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the biopharmaceutical company, with a 17,500p price target, representing 46% potential upside from its 11,958p share price. The broker expects AstraZeneca to report third-quarter revenue about 1% ahead of the Visible Alpha consensus and core earnings before interest and tax at 3% above expectations.

Citi raised its target price for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, to £186 from £178 and retained its 'buy' rating after recent clinical developments. The broker increased its peak sales forecast for tozorakimab to $7 billion and for SERENA-6 to $1.1 billion, more than offsetting the removal of its $1.7 billion forecast for SERENA-4.

AstraZeneca CEO Pascal Soriot told CNBC that Summit Therapeutics' lead drug could help power next-generation cancer combinations that could be the "future of cancer care." Soriot spoke exclusively with CNBC from the site of AstraZeneca's new more than $1 billion research and development facility in Kendall Square in Cambridge, Massachusetts.

AstraZeneca said on Monday it would spend more than $1 billion in Massachusetts ​as part of its broader $50 billion US ‌investment plan, a move expected to expand its workforce in the state by more than 50% in ​the coming years.

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the opening of its newest global strategic research and development (R&D) center, in Kendall Square, Cambridge, Massachusetts. The new state-of-the-art facility builds on the Company's existing presence in Cambridge and Boston and places its scientists at the heart of one of the world's most innovative life sciences ecosystems. Toge...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody. Pursuant to the terms of the Securities Pu...

AstraZeneca and Daiichi Sankyo have entered into ​a clinical collaboration with ‌Summit Therapeutics to test their cancer drug, Datroway, in ​combination with Summit's ​ivonescimab across multiple tumour types, ⁠including lung and breast ​cancers.

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with Datroway® (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate (AD...